Logo

Caprion Taps McGill University to Help Expand Its Proteomics Effort

Feb 27, 2002

NEW YORK, Feb. 27 - Caprion Pharmaceuticals has asked neighboring McGill University to help expand its proteomics research, the company said on Wednesday.

Terms of this open-ended agreement call for Caprion to give McGill roughly C$1 million for certain proteomics research performed by John Bergeron, chair of the anatomy and cell biology department at McGill who also is Caprion's chief scientific officer for proteomics. 

 

Caprion said it will have access to certain IP to any "technical innovations" developed under the collaboration, along with exclusive rights to license any proteomic technologies that may develop.

 

"Partnering with Caprion provides significant long-term funding that is not always available to our academic researchers," Pierre Bélanger, vice principal for research at McGill, said in a statement. Abe Fuks, dean of medicine at the school, added that the alliance "supports fundamental research at McGill while helping train the next generation of graduates to better meet industrial needs."

 

Caprion and McGill are both based in Montreal.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.